ES2170922T3 - Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos. - Google Patents

Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos.

Info

Publication number
ES2170922T3
ES2170922T3 ES97400990T ES97400990T ES2170922T3 ES 2170922 T3 ES2170922 T3 ES 2170922T3 ES 97400990 T ES97400990 T ES 97400990T ES 97400990 T ES97400990 T ES 97400990T ES 2170922 T3 ES2170922 T3 ES 2170922T3
Authority
ES
Spain
Prior art keywords
lipophille
matrices
controlled release
stabilized
active principles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97400990T
Other languages
English (en)
Inventor
Gilles Fonknechten
Patrick Genty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Application granted granted Critical
Publication of ES2170922T3 publication Critical patent/ES2170922T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS MATRICES LIPOFILAS ESTABILIZADAS PARA LA OBTENCION DE COMPOSICIONES FARMACEUTICAS PARA LA LIBERACION CONTROLADA DE PRINCIPIOS ACTIVOS.
ES97400990T 1996-05-06 1997-05-02 Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos. Expired - Lifetime ES2170922T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9605606A FR2748209B1 (fr) 1996-05-06 1996-05-06 Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs

Publications (1)

Publication Number Publication Date
ES2170922T3 true ES2170922T3 (es) 2002-08-16

Family

ID=9491845

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97400990T Expired - Lifetime ES2170922T3 (es) 1996-05-06 1997-05-02 Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos.

Country Status (16)

Country Link
EP (1) EP0806202B1 (es)
JP (1) JP3983339B2 (es)
CN (1) CN1171270A (es)
AT (1) ATE212543T1 (es)
AU (1) AU720146B2 (es)
CA (1) CA2204475C (es)
DE (1) DE69710121T2 (es)
DK (1) DK0806202T3 (es)
ES (1) ES2170922T3 (es)
FR (1) FR2748209B1 (es)
HU (1) HU222045B1 (es)
NO (1) NO318227B1 (es)
NZ (1) NZ314740A (es)
PL (1) PL190562B1 (es)
PT (1) PT806202E (es)
ZA (1) ZA973836B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
DK1660047T3 (en) 2003-08-13 2014-03-10 Biocon Ltd MICROPARTICALLY FATIC ACID SALT SOLID DOSAGE FORMS FOR THERAPEUTIC AGENTS
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
CN101360485B (zh) 2005-10-26 2013-04-17 班纳制药公司 作为胶囊填充物的基于亲水性载体的双重控释基质系统
JP5406529B2 (ja) * 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate

Also Published As

Publication number Publication date
FR2748209A1 (fr) 1997-11-07
CN1171270A (zh) 1998-01-28
EP0806202A1 (fr) 1997-11-12
PT806202E (pt) 2002-06-28
PL319808A1 (en) 1997-11-10
CA2204475A1 (fr) 1997-11-06
JPH1045629A (ja) 1998-02-17
NO972068D0 (no) 1997-05-05
HU222045B1 (hu) 2003-04-28
AU720146B2 (en) 2000-05-25
CA2204475C (fr) 2002-12-03
NZ314740A (en) 1998-11-25
JP3983339B2 (ja) 2007-09-26
DK0806202T3 (da) 2002-05-06
AU1999197A (en) 1997-11-13
ZA973836B (en) 1997-12-02
NO972068L (no) 1997-11-07
FR2748209B1 (fr) 1998-06-05
HUP9700842A1 (hu) 1998-08-28
HU9700842D0 (en) 1997-06-30
NO318227B1 (no) 2005-02-21
DE69710121T2 (de) 2002-11-28
EP0806202B1 (fr) 2002-01-30
DE69710121D1 (de) 2002-03-14
ATE212543T1 (de) 2002-02-15
PL190562B1 (pl) 2005-12-30

Similar Documents

Publication Publication Date Title
BR9916835A (pt) Composição de galantamina de liberação controlada
HN1997000072A (es) Procedimiento para la preparacion de sildenafil
HN1999000066A (es) Formulaciones farmaceuticas
EA200000584A2 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
HN1998000113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
HN2001000190A (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
ES2189256T3 (es) Composiciones de mezclas de ester de cianoacrilato.
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
HN1998000166A (es) Compuesto de benceno sustituido procedimiento para su preparacion y composiciones herbicidas y defoliantes que los contienen.
PT948320E (pt) Composicoes farmacologicas para a libertacao sustentada de fluvastatina inibidora da redutase de hmg-coa
HN1998000144A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
ES2170922T3 (es) Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos.
HN2000000060A (es) Composiciones solidad que contienen gabapentina y proceso para su preparacion.
SE9801494D0 (sv) Novel use
HN1998000106A (es) Composiciones parenterales de alatroflaxacino
HN1998000045A (es) Composiciones farmaceuticas
ES2160978T3 (es) Composiciones farmaceuticas estabilizadas y procedimiento para su preparacion.
BR9810725A (pt) Formulações aperfeiçodas de gel contendo inseticida
SV1998000013A (es) Derivados de 5-aroilnaftaleno ref.-ran 4070\115
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
EA200000112A1 (ru) Новая композиция
ES2185666T3 (es) Formulacion estabilizada para comprimidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 806202

Country of ref document: ES